Highlights
Thyroid hormones (THs) may play a previously underrecognized role in autosomal dominant polycystic kidney disease (ADPKD), a leading inherited cause of kidney failure. In patient-derived 3D renal epithelial models, thyroxine (T4) suppressed cyst growth through αvβ3 integrin-dependent signaling and effects on proliferative, metabolic, and ferroptotic pathways. In PCK rats, T4 reduced kidney enlargement and macrocystic burden. In a 90-patient ADPKD cohort, lower free triiodothyronine (fT3) and higher reverse triiodothyronine (rT3) were associated with worse renal function, suggesting potential prognostic value.
Study Background and Unmet Need
ADPKD is a progressive genetic disorder caused primarily by pathogenic variants in PKD1 or PKD2, leading to lifelong cyst formation, kidney enlargement, hypertension, and gradual decline in glomerular filtration rate. Despite improved understanding of disease biology, treatment options remain limited. Tolvaptan is currently the main disease-modifying therapy, but its use is constrained by aquaresis-related adverse effects, liver monitoring requirements, and variable tolerability. This creates a substantial unmet need for additional therapies that can target cystogenesis through complementary mechanisms.
Thyroid hormones are classically known for regulating systemic metabolism, growth, and development, but they also influence renal physiology and cellular stress responses. Prior work in other kidney diseases has linked thyroid status to renal hemodynamics, fibrosis, and outcomes. However, whether THs contribute directly to ADPKD pathobiology had not been established. The study by Lavecchia and colleagues addresses this gap by combining mechanistic cell studies, an animal model, and clinical biomarker analysis.
Study Design
This translational investigation used three complementary approaches. First, patient-derived renal epithelial cells were used to engineer 3D polycystic tubules, allowing the investigators to test the anti-cystogenic effects of thyroxine and related compounds under controlled experimental conditions. Second, the therapeutic effect of T4 was evaluated in vivo in PCK rats, a recognized animal model of ADPKD. Third, serum TH levels were measured in 90 patients enrolled in the REORIENTED clinical study (Clinical Trial Gov NCT05646420) and correlated with estimated glomerular filtration rate to assess clinical relevance.
The main experimental endpoints were cyst growth, cyst burden, kidney weight, and mechanistic pathway activation. Clinical endpoints focused on associations between circulating TH metabolites and renal function. Because this was a mechanistic and exploratory translational study rather than a randomized clinical trial, the findings are hypothesis-generating and intended to support future interventional research.
Key Findings
The most notable experimental result was that thyroxine inhibited cyst growth through binding to αvβ3 integrin, a cell-surface receptor known to mediate non-genomic thyroid hormone signaling. This effect was linked to downstream modulation of proliferative pathways, metabolic reprogramming, and ferroptosis-related signaling. Ferroptosis is an iron-dependent form of regulated cell death that has recently attracted attention in cystic and fibrotic kidney disease because of its relationship to oxidative stress and lipid peroxidation.
In the PCK rat model, T4 administration produced a measurable structural benefit. Kidney weight decreased, and the macrocystic area was significantly reduced compared with vehicle treatment. The reported macrocystic area was 9.255 ± 2.654% in the vehicle group versus 1.945 ± 0.850% with T4, with p < 0.05. This is a sizable effect in a preclinical model and supports a true biological signal rather than a marginal laboratory phenomenon. That said, the exact clinical magnitude in humans remains unknown.
The human biomarker data were also intriguing. In the overall ADPKD cohort, rT3 levels inversely correlated with renal function (R2 = 0.159, r = -0.397, p < 0.001), while fT3 levels showed a positive correlation (R2 = 0.110, r = 0.332, p < 0.01). In practical terms, patients with lower fT3 or higher rT3 tended to have worse kidney function. These associations do not prove causality, but they raise the possibility that thyroid hormone profiles may reflect disease severity or metabolic stress in ADPKD.
Importantly, the study does not yet establish whether altered thyroid hormone levels are a driver of cyst progression, a consequence of kidney disease, or both. In advanced chronic kidney disease, non-thyroidal illness patterns, altered deiodination, and changes in hormone clearance can all influence circulating thyroid markers. Therefore, the biomarker findings should be interpreted cautiously and in the broader context of kidney–thyroid interactions.
Mechanistic Interpretation
The proposed mechanism centers on T4 interaction with αvβ3 integrin, a pathway that can activate intracellular signaling without requiring classical nuclear thyroid receptor binding. This is clinically interesting because it implies that TH effects in ADPKD may be rapid and membrane-mediated rather than exclusively genomic. The study suggests that thyroid hormone signaling may intersect with core ADPKD biology by affecting cell proliferation, metabolic state, and susceptibility to ferroptosis.
From a translational perspective, this is important because cyst growth in ADPKD is driven by abnormal epithelial proliferation, fluid secretion, energy metabolism changes, and inflammatory-fibrotic responses. A therapy that modulates several of these processes simultaneously could be attractive, especially if it can be administered alongside existing disease-modifying treatment. However, thyroid hormones are pleiotropic and systemically active; any therapeutic strategy would require careful balancing of renal benefit against cardiovascular, skeletal, and metabolic risks.
Clinical Relevance and Practical Implications
If validated, TH profiling could contribute to risk stratification in ADPKD. fT3 and rT3 are inexpensive, widely available assays, and their correlation with renal function suggests potential value as adjunctive biomarkers. In particular, they may help identify patients with more advanced disease biology or those at risk for faster progression. Nevertheless, biomarker use in clinical practice would require prospective validation, standardized timing of sampling, and adjustment for confounders such as inflammation, nutritional status, medication use, and degree of kidney dysfunction.
The therapeutic signal is even more provocative. T4 reduced cyst burden in an animal model and suppressed cyst growth in human-derived 3D cultures, suggesting that thyroid hormone modulation could be explored as a new treatment axis in ADPKD. But this should not be interpreted as support for off-label thyroid hormone administration in patients. Thyroxine replacement or suppression therapy can cause atrial fibrillation, tachycardia, bone loss, and overt thyrotoxicosis if used inappropriately. Any future clinical application would likely require selective modulation of signaling pathways rather than routine endocrine replacement.
Strengths of the Study
This work has several strengths. It integrates mechanistic, preclinical, and human observational data into a single translational framework. The use of patient-derived cells increases biological relevance compared with immortalized cell lines. The PCK rat experiment provides in vivo support, while the clinical cohort offers early evidence that the endocrine findings may matter in actual patients. The identification of αvβ3 integrin as a plausible signaling node also gives the field a testable target for future pharmacology.
Limitations and Cautionary Notes
Several limitations should temper enthusiasm. First, the study appears exploratory and not designed to demonstrate clinical efficacy in humans. Second, the clinical data are cross-sectional and correlational, so they cannot distinguish cause from effect. Third, the sample size of 90 patients is relatively modest for biomarker inference, especially in a disease as heterogeneous as ADPKD. Fourth, the abstract does not provide detailed confidence intervals, subgroup analyses, or adjustment for potential confounders such as age, sex, body composition, inflammation, and thyroid medication use. Finally, preclinical benefits in rodents often overestimate what can be achieved in human disease.
There is also an important physiological caveat: thyroid hormone biology in chronic kidney disease is complex. Low T3 states are common in chronic illness and may reflect systemic stress rather than a disease-specific pathway. Distinguishing adaptive changes from pathogenic signaling will be essential before TH-related biomarkers or therapies can be adopted in routine nephrology practice.
Expert Commentary
From a nephrology standpoint, this study is best viewed as a proof-of-concept that endocrine pathways outside the kidney may influence cystic kidney disease. ADPKD is increasingly understood as a multisystem disorder with altered energy metabolism, ciliary signaling defects, and inflammatory remodeling. The present findings fit that broader model and suggest that thyroid hormone signaling deserves further study. From an endocrine perspective, the data also reinforce the idea that “normal” thyroid physiology may not be neutral in chronic kidney disease states, particularly when organ-specific signaling pathways are altered.
The most clinically meaningful next step would be a prospective study evaluating whether baseline TH profiles predict ADPKD progression independent of established risk models, such as total kidney volume, genotype, age, and eGFR trajectory. A subsequent interventional trial would need to define whether targeted thyroid signaling modulation can slow disease without causing systemic hyperthyroid toxicity. Until then, the findings are exciting but not practice-changing.
Conclusion
Lavecchia and colleagues provide compelling translational evidence that thyroid hormones may influence ADPKD progression and that T4 can reduce cyst growth in experimental systems. The association of fT3 and rT3 with renal function in patients suggests possible prognostic relevance, while mechanistic work implicates αvβ3 integrin-mediated signaling and downstream metabolic and ferroptotic pathways. Together, these findings open a new research direction at the intersection of nephrology and endocrinology. For now, the study should be interpreted as a strong biological signal that justifies larger validation studies rather than immediate clinical use.
Funding and Clinical Trial Registration
The abstract identifies the REORIENTED clinical study and its registration number, Clinical Trial Gov NCT05646420. The funding source is not specified in the provided material.
References
1. Lavecchia AM, Locatelli L, Trillini M, Del Vecchio A, Cerullo D, Villa A, Peracchi T, Brizi V, Buttò S, Corna D, Brunelli L, Guarinoni C, Rubis N, Remuzzi G, Xinaris C. Thyroid Hormones Exhibit Promising Prognostic and Therapeutic Potential in Autosomal Dominant Polycystic Kidney Disease. Thyroid. 2026-06-15:10507256261460200. PMID: 42296046.
2. Torres VE, Harris PC, Pirson Y. Autosomal dominant polycystic kidney disease. Lancet. 2007;369(9569):1287-1301.
3. Chebib FT, Torres VE. Recent advances in the management of autosomal dominant polycystic kidney disease. Clin J Am Soc Nephrol. 2021;16(7):1104-1115.
4. Gattineni J. The kidney in thyroid hormone metabolism and action. Pediatr Nephrol. 2012;27(11):1875-1881.
5. Kaptein EM, Quion-Verde H, Chooljian CJ, Tang WW, Friedman PE, Rodriquez HJ. The thyroid in end-stage renal disease. Medicine (Baltimore). 1988;67(3):187-197.